In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neena Brizmohun

Deputy Editor

Neena has over 20 years of experience covering regulatory, business and market access developments that impact pharmaceutical and medical device companies. She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, pricing and reimbursement, clinical trials, real-world evidence, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.

Latest From Neena Brizmohun

Canada Addresses Diversity In Clinical Trials With New Rule For Drug Filings

Health Canada wants drug sponsors to start answering questions relating to disaggregated data for sex, age and race.

Clinical Trials Canada

Codeine/Ibuprofen Combo Safety Concerns Prompt EMA Call For Prescription-Only Status

Drugs combining codeine and ibuprofen were among the latest products for which the European Medicines Agency has recommended new risk minimization measures –Imbruvica and terlipressin-containing medicines were the others.

Europe Drug Safety

New EU Filings

Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.

Drug Review Europe

Novel Brain Penetrant For Treating X-ALD Among Raft Of New EU Filings

Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.

Europe Approvals

AB Science & Daiichi Try Their Luck Again With EU Filings

The sponsors of Alsitek and quizartinib are hoping that new data generated for the drugs will resolve the concerns raised by the European Medicines Agency when it previously rejected the products for marketing in the EU.

Drug Review Europe

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add seven new products, including Nulibry, BridgeBio/Sentynl's orphan drug for treating molybdenum cofactor deficiency Type A.

Europe Approvals
See All
UsernamePublicRestriction

Register